Pipeline
We are dedicated to reimagining how cancer is treated and focused on developing potential first- and best-in-class solutions that support patient journeys. With a determination to realize a future in which people with cancer live longer and better than ever before, Syndax is unwaveringly committed to delivering new treatment options for cancer patients that provide meaningful and differentiated results.
We have a proven ability to advance innovative and differentiated cancer programs and a strong record of adhering to scientific excellence, following promising clinical data and real-world utilization.
Revumenib and axatilimab have the potential to be approved in the U.S. in 2024, with several opportunities for franchise expansion.
Revumenib
Menin-KMT2A Disruption
Phase 1
Phase 2
Pivotal
Registration
Indication(s)
Stage
AUGMENT-101-2A
monotherapy
R/R KMT2Ar ALLregistrationAUGMENT-101-2B
monotherapy
R/R KMT2Ar AMLregistrationAUGMENT-101-2C
monotherapy
R/R NPM1m AMLpivotalAUGMENT-102
chemotherapy combination
R/R KMT2Ar and NPM1m acute leukemiasphase-1BEAT-AML
ven/aza combination
Frontline KMT2Ar and NPM1m AMLphase-1INTERCEPT
monotherapy
MRD- progression in KMT2Ar and NPM1m AMLphase-1Colorectal Cancer
monotherapy
Unresectable metastatic microsatellite stable CRCphase-17+3
intensive chemotherapy combination
Newly diagnosed NPM1m or KMT2Ar acute leukemiasphase-1
Axatilimab
Anti-CSF-1R mAb
Phase 1
Phase 2
Pivotal
Registration
Indication(s)
Stage
AGAVE-201
monotherapy
Chronic GVHDregistrationIdiopathic Pulmonary Fibrosis
monotherapy
Idiopathic Pulmonary Fibrosisphase-2
Entinostat
Class 1 HDAC Inhibitor
Under regulatory review in China